[en] This study aimed at a better understanding of estrogen receptor alpha (ER) up regulation induced by partial estrogen antagonists. Effect of treatment with hydroxytamoxifen (OH-Tam) on ER level in MCF-7 cells was investigated by an approach combining ER measurement (enzyme immunoassay) and morphological demonstration (immunofluorescence). Furthermore, the influence of drug exposure on the rates of ER synthesis and degradation was assessed by determining [35S]methionine incorporated into the receptor in different experimental conditions (measurement of synthesis or pulse-chase experiments). ER up regulation was already induced by a 1-h pulse treatment with OH-Tam, thus a continuous exposure was not required. This process appeared reversible (i.e. ER accumulation due to OH-Tam rapidly vanished upon subsequent exposure to 17beta-estradiol (E2) or the pure antiestrogen RU 58668). While OH-Tam did not affect the rate of [35S]methionine incorporation into ER, it clearly caused an impairment of ER degradation (pulse-chase experiments) indicating that up regulation results from a stabilization of the receptor associated with the maintenance of its synthesis. Various tamoxifen derivatives, as well as a few related partial antiestrogens, were compared on the basis of binding ability and propensity to induce ER up regulation. A close relationship was found between both properties. Structure-activity analysis revealed that the capacity of these compounds to induce ER up regulation is associated with characteristics of their aminoalkyle side-chain, similar to those required for antiestrogenicity
Favoni R.E., de Cupis A. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends Pharmacol. Sci. 19:1998;406-415.
Green S., Furr B. Prospects for the treatment of endocrine-responsive tumours. Endocr. Relat. Cancer. 6:1999;349-371.
Pritchard K.I. Current and future directions in medical therapy for breast carcinoma. Cancer. 88:2000;3065-3072.
Plouffe L. Selective estrogen receptor modulators (SERMs) in clinical practice. J. Soc. Gynecol. Investig. 7:2000;S38-S46.
Kiang D.T., Kollander R.E., Thomas T., Kennedy B.J. Up-regulation of estrogen receptors by non-steroidal antiestrogens in human breast cancer. Cancer Res. 49:1989;5312-5316.
Gyling M., Leclercq G. Estrogenic and antiestrogenic down-regulation of estrogen receptor levels, evidence for two different mechanisms. J. Recept. Res. 10:1990;217-234.
Leclercq G., Legros N., Piccart M.J. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment. J. Steroid Biochem. Mol. Biol. 41:1992;545-552.
Jin L., Borrás M., Lacroix M., Legros N., Leclercq G. Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells. Steroids. 60:1995;512-518.
Legros N., Jin L., Leclercq G. Tamoxifen-induced estrogen receptor up-regulation in mammary tumor cells is not related to growth inhinition. Cancer Chemother. Pharmacol. 39:1997;380-382.
Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106:1993;1377-1388.
Devin-Leclerc J., Meng X., Delahaye F., Leclerc P., Baulieu E.-E., Catelli M.-G. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol. Endocrinol. 12:1998;842-854.
Oesterreich S., Zhang Q., Hopp T., Fuqua S.A.W., Michaelis M., Zhao H.H., Davie J.R., Osborne C.K., Lee A.V. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol. Endocrinol. 14:2000;369-381.
El Khissiin A., Journé F., Laïos I., Seo H.-S., Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids. 65:2000;903-913.
Lee H., Jiang F., Wang Q., Nicosia S.V., Yang J., Su B., Bai W. MEKK1 activation of human estrogen receptor α and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol. 14:2000;1882-1896.
Sakamoto T., Eguchi H., Omoto Y., Ayabe T., Mori H., Hayashi S. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol. Cell. Endocrinol. 192:2002;93-104.
Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
Seo H.-S., Journé F., Larsimont D., Sotiriou C., Leclercq G. Decrease of estrogen receptor expression and associated ERE-dependent transcription in MCF-7 breast cancer cells under oligomycin treatment. Steroids. 68:2003;257-269.
Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
Brohée R., Nonclercq D., Journé F., Toubeau G., Falmagne P., Leclercq G., Heuson-Stiennon J.-A., Laurent G. Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors. In Vitro Cell. Dev. Biol. Anim. 36:2000;640-649.
Stoessel S., Leclercq G. Competitive binding assay for estrogen receptor in monolayer culture: measure of receptor activation potency. J. Steroid Biochem. 25:1986;677-682.
El Khissiin A., Leclercq G. Exchange of bound estrogens and antiestrogens in MCF-7 cells: evidence for ligand-induced stable configurations of the estrogen receptor. Steroids. 63:1998;565-574.
El Khissiin A., Leclercq G. Implication of proteasome in estrogen receptor degradation. FEBS Lett. 448:1999;160-166.
Foster A.B., Jarman M., Leung O.-T., McCague R., Leclercq G., Devleeschouwer N. Hydroxy derivatives of tamoxifen. J. Med. Chem. 28:1985;1491-1497.
Jordan V.C., Lieberman M.E., Cormier E., Koch R., Bagley J.R., Ruenitz P.C. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Mol. Pharmacol. 26:1984;272-278.
Murphy C.S., Langan-Fahey S.M., McCague R., Jordan V.C. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol. Pharmacol. 38:1990;737-743.
Robertson D.W., Katzenellenbogen J.A., Hayes J.R., Katzenellenbogen B.S. Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (z)-1,2-diphenyl-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity. J. Med. Chem. 25:1982;167-171.
Grese T.A., Sluka J.P., Bryant H.U., Cullinan G.J., Glasebrook A.L., Jones C.D., Matsumoto K., Palkowitz A.D., Sato M., Termine J.D., Winter M.A., Yang N.N., Dodge J.A. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. U.S.A. 94:1997;14105-14110.
Jin L., Legros N., Leclercq G., Hardcastle I., Jarman M. Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast cancer cell lines. Cancer Chemother. Pharmacol. 41:1998;339-342.
Eckert R.L., Mullick A., Rorke E.A., Katzenellenbogen B.S. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology. 114:1984;629-637.
Monsma F.J., Katzenellenbogen B.S., Miller M.A., Ziegler Y.S., Katzenellenbogen J.A. Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covanlently attaching antiestrogen. Endocrinology. 115:1984;143-153.
Nardulli A.M., Katzenellenbogen B.S. Dynamics of estrogen receptor turnover in uterine cells in vitro and uteri in vivo. Endocrinology. 119:1986;2038-2046.
Stoica A., Saceda M., Fakhro A., Solomon H.B., Fenster B.D., Martin M.B. The role of transforming growth factor-β in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology. 138:1997;1498-1505.
Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4037-4041.
Borrás M., Laios I., El Khissiin A., Seo H.-S., Lempereur F., Legros N., Leclercq G. Estrogenic and antiestrogenic regulation of the half-life of convalently labeled estrogen receptor in MCF-7 breast cancer cells. J. Steroid. Biochem. Mol. Biol. 57:1996;203-213.
Wijayaratne A.E., McDonnell D.P. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276:2001;35684-35692.
Pearce S.T., Liu H., Jordan V.C. Modulation of estrogen receptor (function and stability by tamoxifen and a critical amino acid (D538) in helix 12. J. Biol. Chem. 278:2003;7630-7638.
Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (London). 389:1997;753-758.
Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
MacGregor-Schafer J., Liu H., Bentrem D.J., Zapf J.W., Jordan V.C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 60:2000;5097-5105.
Levenson A.S., Jordan V.C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58:1998;1872-1875.
Alarid E.T., Bakopoulos N., Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol. Endocrinol. 13:1999;1522-1534.
Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1858-1862.
Preisler-Mashek M.T., Solodin N., Stark B.L., Tyriver M.K., Alarid E.T. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-α Am. J. Physiol. Endocrinol. Metab. 282:2002;E891-E898.
Lonard D.M., Nawaz Z., Smith C.L., O'Malley B.W. The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol. Cell. 5:2000;939-948.
Dennis A.P., Haq R.U., Nawaz Z. Importance of the regulation of nuclear receptor degradation. Front. Biosci. 6:2001;D954-D959.
Stoner M., Saville B., Wormke M., Dean D., Burghardt R., Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75 breast cancer cells. Mol. Endocrinol. 16:2002;2231-2242.
Lange C.A., Shen T., Horwitz K.B. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1032-1037.
Lee M.-O., Kim E.-O., Kwon H.J., Kim Y.M., Kang H.-J., Kang H., Lee J.-E. Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Mol. Cell. Endocrinol. 188:2002;47-54.
Rivett J.A. Intracellular distribution of proteasomes. Curr. Opin. Immunol. 10:1998;110-114.
Hirsch C., Ploegh H.L. Intracellular targeting of the proteasome. Trends Cell Biol. 10:2000;268-272.
Pollenz R.S. The mechanism of AH receptor protein down-regulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem. Biol. Interact. 141:2002;41-61.
Blazejewski J.C., Wilmshurst M.P., Popkin M.D., Wakselman C., Laurent G., Nonclercq D., Cleeren A., Ma Y., Seo H.-S., Leclercq G. Synthesis, characterization and biological evaluation of 7α-perfluoroalkylestradiol derivatives. Bioorg. Med. Chem. 11:2003;335-345.
F. Journé, J.-J. Body, G. Leclercq, D. Nonclercq, G. Laurent, Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma, submitted for publication.
